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Abstract
Objective: The HIV epidemic has increased the proportion of patients with smear-negative and extrapulmonary tuberculosis
(TB) diagnoses, with related higher rates of poor TB treatment outcomes. Unlike in smear-positive pulmonary TB, no interim
markers of TB treatment progress are systematically used to identify individuals most at risk of mortality. The objective of
this study was to assess the association of body mass index (BMI) change at 1 month (615 days) from TB treatment start
with mortality among HIV-positive individuals with smear-negative and extrapulmonary TB.
Methods and Findings: A retrospective cohort study of adult HIV-positive new TB patients in Me ´decins Sans Frontie `res
(MSF) treatment programmes in Myanmar and Zimbabwe was conducted using Cox proportional hazards regression to
estimate the association between BMI category change and mortality. A cohort of 1090 TB patients (605 smear-negative and
485 extrapulmonary) was followed during TB treatment with mortality rate of 28.9 per 100 person-years. In multivariable
analyses, remaining severely underweight or moving to a lower BMI category increased mortality (adjusted hazard ratio
4.05, 95% confidence interval 2.77–5.91, p,0.001) compared with remaining in the same or moving to a higher BMI
category.
Conclusions: We found a strong association between BMI category change during the first month of TB treatment and
mortality. BMI category change could be used to identify individuals most at risk of mortality during TB treatment among
smear-negative and extrapulmonary patients.
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Introduction
In 2010, approximately 8.8 million incident cases of tuberculosis
(TB) occurred, 1.45 million people died from the disease and 24%
of those who died were co-infected with the human immunode-
ficiency virus (HIV) [1]. In countries with a high prevalence of
HIV, HIV-positive individuals have a 20-fold increased risk of
developing TB compared with those who are HIV-negative [2].
Antiretroviral therapy (ART) can substantially reduce TB
incidence among HIV-positive patients [3]. However, TB slows
immunological recovery among patients on ART [4], and
mortality after initiation of TB treatment is higher among HIV-
positive patients [5–10]. In South Africa, TB incidence rates
remained two-fold among HIV-positive patients with CD4 cell
counts .500/mm
3, compared with HIV-negative individuals [6].
TB is more likely to be smear-negative and extrapulmonary in
HIV-positive than in HIV-negative patients, irrespective of ART
status [6,11]. Overall, 63% of 5,930 adult HIV-positive TB
patients with information on clinical presentation enrolled in TB
treatment by Me ´decins Sans Frontie `res (MSF) in six countries
between January 2006 and September 2008 were smear-negative
or extrapulmonary [12]. These patients are at higher risk of TB
treatment default and mortality, partly as a result of delayed
diagnosis and treatment [7,13,14]. Both Zimbabwe and Myanmar
are in the WHO ‘high TB burden’ category and most notified new
TB cases in both countries (51% and 66%, respectively) are either
smear-negative or extrapulmonary [15,16].
WHO guidelines on interim indicators of treatment success in
TB patients focus on smear-positive patients (i.e. cohort smear
conversion rate of 80% in month 2 of TB treatment). No
prognostic indicators are currently systematically applied among
smear-negative and extrapulmonary TB patients to identify those
at increased risk of unfavourable TB treatment outcomes. HIV-
related malnutrition increases the risk of TB [17,18] and is
exacerbated by TB, with a negative overall impact on mortality
[10,19–21]. Among patients with HIV, those diagnosed with
pulmonary TB have lower body mass index (BMI) and weight
than those without TB [22]. In HIV patients without TB, higher
BMI is associated with better survival outcomes [23] and low BMI
is a predictor for mortality even in patients receiving ART [18].
PLoS ONE | www.plosone.org 1 April 2012 | Volume 7 | Issue 4 | e35948If it is successful, TB treatment should result in weight gain
among underweight individuals through restoring muscle and fat
mass, depending on nutritional intake [19]. Previous studies on
cohorts of mixed HIV status have shown that weight changes
during early TB treatment can be useful indicators of TB
treatment outcomes [24,25]. However, the association of this
indicator has not yet been assessed among smear-negative and
extrapulmonary HIV-positive patients.
In this study, we aimed to establish how changes in BMI
category after the first month of TB treatment in new adult smear-
negative and extrapulmonary patients co-infected with HIV were
associated with mortality during TB treatment.
Materials and Methods
Routinely collected patient data from three MSF TB treatment
programmes (Shan and Yangon in Myanmar, Gweru in
Zimbabwe) were used in this retrospective cohort study. Data
from electronic HIV and TB databases were merged and all HIV-
positive patients starting treatment for smear-negative or extra-
pulmonary tuberculosis between February 6, 2003 and July 17,
2010 were identified. Smear-negative and extrapulmonary TB
were diagnosed according to the recommended WHO algorithm
[26]. Acid-fast bacilli smear tests were available for diagnosis; no
cultures were performed. No diagnosis or treatment for drug-
resistant TB was available.
Inclusion was limited to new, adult TB patients, defined as
patients who had not taken TB drugs for more than 30 days within
the five years preceding current TB treatment and who were $15
years at the start of TB treatment. To enable measurement of BMI
category change between the start and one month of TB
treatment, only patients followed at least until day 15 of TB
treatment were considered.
Patients without a recorded TB treatment outcome were
excluded (e.g. those who transferred to another healthcare
provider during treatment). Further, only patients with a weight
measurement at the start of TB treatment (within 615 days of
treatment start date) and one month after TB treatment start
(between 15 and 45 days from treatment start date), as well as a
height measurement anytime during TB treatment, were included
(Figure 1).
Our main outcome measure was all-cause mortality during TB
treatment and our secondary outcome was unfavourable TB
treatment outcome (combination of death, default and treatment
failure). The binary exposure, change in BMI category between
the start and one month of TB treatment, was defined as
remaining severely underweight or moving to a lower BMI
category versus remaining in the same or moving to a higher BMI
category. BMI was calculated by dividing the weight in kilograms
by square of height in meters and categorized according to
standard definitions (severely underweight: ,16; underweight
16.00–18.49; normal 18.5–24.99; overweight and obese $25, kg/
m
2).
MSF guidelines on the timing of initiation of ART in HIV-
positive TB patients changed during the study. In Myanmar,
before June 2007, all TB patients fulfilled criteria to start ART;
from June 2007 to late 2009, all extrapulmonary TB (irrespective
of CD4 count) and pulmonary TB patients with CD4,350/mm
3
qualified for ART; and from January 2010, all TB cases started
ART irrespective of CD4 count. In Zimbabwe, from 2007 to
2010, all patients with WHO stage 4 and patients with stage 3 with
CD4 count,350/mm
3 started ART. Prior to 2010, if CD4 count
was ,200/mm
3, ART was started within the intensive phase of
TB treatment; if it was $200/mm
3 it was started upon completion
of the intensive phase. As of 2010, TB patients were initiated on
ART regardless of CD4 count as soon as possible after TB
treatment initiation.
Data were analyzed using Stata/SE v.12 (Stata Corporation,
College Station, Texas, USA). Follow-up was measured from start
of TB treatment and ended either on the date TB treatment was
finished (if patients completed treatment); on the date TB
treatment was stopped (if patients failed or defaulted from
treatment), or on the recorded date of death for those who died
during TB treatment.
Cox proportional hazards regression was used to obtain
unadjusted hazard ratios for the effect of BMI category change
on time to death. Each potential confounder was added and
evaluated by its strength in meaningfully adjusting the modelled
hazard ratio for BMI category change. In patients not receiving
ART prior to TB treatment, exposure to ART is likely to change
over the course of TB treatment as they become eligible for ART.
Therefore, ART status was modelled as a binary time-dependent
covariate. This approach allows for person-time at risk in both
categories of ART status to be analyzed more precisely. Project
site, exposure to ART at the start of TB treatment and sex were
considered a priori effect modifiers and assessed in final models
using the likelihood ratio test. Each adjusted Cox proportional
hazards model was assessed to confirm proportionality of hazard
functions with BMI category change. Analysis of the effect of BMI
change on the composite endpoint of unfavourable TB treatment
outcome was conducted using the same modelling approach. In
addition, a sensitivity analysis was conducted on a larger sample of
patients (n=1330) surviving up to day 30 of TB treatment, where
change of BMI category between the start and 2 months of TB
treatment (weight measurements interval 630 days) was assessed.
This study was approved by the Research Ethics Committee of
the London School of Hygiene and Tropical Medicine, UK and
met the standards set by the MSF Ethics Review Board for
retrospective analysis of routinely collected programmatic data.
Figure 1. Intervals for measurement of weight and CD4 count at TB treatment start and 1 month after TB treatment start.
doi:10.1371/journal.pone.0035948.g001
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The final sample consisted of 1090 TB patients (Figure 2), 605
and 485 with smear-negative and extrapulmonary TB, respec-
tively. Among this sample, 34% were from Shan, 29% from
Yangon and 37% from Gweru (Table 1). The median age was 34
years and overall 54% were male. More than 60% of patients were
underweight or severely underweight at the start of TB treatment.
Whereas only 610 (56%) of the overall patient sample had a record
for cotrimoxazole preventive therapy (CPT) status, more than
97% of the patients with a non-missing value received CPT. The
total follow up time was 519.4 person-years and the median follow
up time was 182 days. A total of 150 deaths occurred during TB
treatment (14% of sample), giving an overall mortality rate of 28.9
per 100 person-years (95% confidence interval [CI] 24.6–33.9).
The smear-negative and extrapulmonary patient samples have
similar distributions of demographic and baseline epidemiological
variables, with the exception of the proportion starting ART
before TB treatment start and TB treatment end (Table 2).
During the first month of treatment 27% (299/1090) of TB
patients remained severely underweight or moved to a lower BMI
category. The mortality rate among patients in this group was 61.4
per 100 person-years (95%CI 49.3–76.5), compared with 17.9
(95%CI 14.2–22.7) among those who remained in the same BMI
category or gained a BMI category. Crude analysis showed strong
evidence that the hazard for TB treatment mortality differed by
category of BMI change and this association strengthened when
adjusted for sex, age group, project, ART status and BMI at TB
treatment start (Table 3). Remaining severely underweight or
moving to a lower BMI category had 4.05 times (95%CI 2.77–
5.91, p,0.001) higher mortality rate compared with remaining in
the same or moving to a higher BMI category. Data were
consistent with no interaction of BMI category change with ART
status at TB treatment start (p=0.32), project site (p=0.28) or sex
(p=0.64) and satisfied the assumption of proportional hazards
(p=0.16). Adjusting for CD4 count measured at the start of TB
treatment showed a stronger magnitude of association between
BMI category change and TB treatment mortality (Table 3).
Sensitivity analysis on a sample of 1330 patients surviving up to
day 30 of TB treatment showed that the direction and magnitude
of the association between BMI category change and TB
treatment mortality was very similar to the main model presented
(Appendix S1). Lastly, those who remained severely underweight
or lost a BMI category had over twice the rate of unfavourable TB
treatment outcomes compared to those who remained in the same
or moved to a higher BMI category (adjusted HR 2.53, 95%CI
1.87–3.42; Appendix S2).
Discussion
Our results show a strong association between BMI category
change during early TB treatment and TB treatment outcomes
(mortality and combined unfavourable outcomes) among HIV-
positive TB smear-negative and extrapulmonary individuals. Our
sizeable study sample included TB patients from three clinical
programmes in two countries.
Figure 2. Flow diagram showing sample construction.
doi:10.1371/journal.pone.0035948.g002
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Overall Project site
Shan Yangon Gweru
n 1090 369 317 404
TB type
Smear-negative (%) 55.5 53.4 52.7 59.7
Extrapulmonary 44.5 46.6 47.3 40.3
Sex
Male (%) 53.9 64.0 59.9 39.9
Age (years)
Median 34.0 33.2 32.3 36.3
IQR 29.5–40.2 29.9–39.1 28.1–38.1 30.8–43.5
Weight at TB treatment start (kg)
Median 47 45 44 51
IQR 41–53 39–51 39.5–50 45–57
BMI category at TB treatment start (kg/m
2)
,16 (%) 23.6 27.9 27.4 16.6
16–18.49 36.8 41.7 38.5 30.9
18.5–24.99 36.8 29.3 32.2 47.3
$25 2.8 1.1 1.9 5.2
TB treatment regimen
2RHEZ/4RH (%)* 98.4 99.4 99.5 96.5
ART status at TB treatment start
Prior to TB treatment (%) 21.3 22.2 16.1 24.5
Within 2 weeks of TB treatment 8.7 5.4 15.8 6.2
Within 2–4 weeks of TB treatment 18.0 18.2 22.1 14.6
After 4 weeks of TB treatment 31.9 26.0 34.0 35.6
After end of TB treatment 20.1 28.2 12.0 19.1
TB treatment duration (days)
Median 182 180 179 184
IQR 169–192 164–192 169–190 181–196
Range 20–349 20–349 34–329 21–294
Subsamples with non-missing values
CPT before TB treatment start
n 610 123 84 403
Yes (%) 97.4 99.2 95.2 97.3
CD4 count at TB treatment start (/mm
3)
n 557 207 157 193
Median 82 70 95 84
#100 (%) 57.8 64.2 50.3 57.0
101–200 21.5 15.5 31.9 19.7
201–350 14.2 14.0 14.0 14.5
.350 6.5 6.3 3.8 8.8
Haemoglobin at TB treatment start (g/dL)
n 434 116 119 199
Median 9.5 9.8 9.5 9.3
#8.5 (%) 35.0 38.8 28.6 36.7
*2 months of rifampicin (R), isoniazid (H), pyrazinamide (Z), ethambutol (E), followed by 4 months of rifampicin (R) and isoniazid (H). Patients not on this recommended
regimen were either receiving different treatment due to side effects, or were receiving streptomycin instead of ethambutol with a diagnosis of extrapulmonary
meningitis.
IQR=interquartile range. ART=antiretroviral therapy. BMI=body mass index. CPT=cotrimoxazole preventive therapy. TB=tuberculosis.
doi:10.1371/journal.pone.0035948.t001
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TB patients, after adjustment, remaining severely underweight or
losing a BMI category in the first month of TB treatment increased
mortality four-fold compared with remaining in the same or
moving to a higher BMI category. The association was even
stronger in a subset of patients after an adjustment was made for
CD4 count at TB treatment start. There is limited guidance on
systematic evaluation of increased risk of death during TB
treatment among HIV-positive smear-negative and extrapulmo-
nary TB patients. Our study shows that a simple binary change in
BMI category during the first month of TB treatment, an
inexpensive measure that is collected and recorded during routine
clinical visits, could be used for interim monitoring of these
patients.
Previous studies have reported that weight gain is a useful
interim marker for favourable TB outcomes in smear-positive TB
patients. Among pulmonary smear-positive patients, unfavourable
TB treatment outcomes were associated with body weight gain of
#5% at the end of TB treatment, although not at one month after
TB treatment start [27]. Further, among new adult TB patients
(pulmonary smear-positive and negative, and extrapulmonary),
weight gain of almost 1 kg after one month on TB treatment was
found to be strongly associated with favourable TB treatment
outcomes. The study also found that most of the change in body
weight differentiating individuals with favourable versus unfavour-
able TB treatment outcomes happened during the first month of
TB treatment and body weight change was found to be an
independent predictor of outcome to interim smear microscopy
conversion [24]. However, both these studies had low numbers of
patients with known HIV status and used weight change (absolute
or relative) as the exposure, a more cumbersome measure than
change in standard BMI categories.
The limitations of this study pertain to the nature of the data,
collected during routine clinical practice. Patients starting TB
Table 2. Association of smear-negative and extrapulmonary TB patient samples with basic demographic and epidemiologic
variables.
Smear-negative Extrapulmonary Chi-square p-value
n 605 485
Sex
Male (%) 54.4 53.2 0.697
Age group
15–24 (%) 6.1 8.0
25–34 45.8 50.9
35–44 31.1 29.1 0.072
45–54 13.0 8.5
55 and above 4.0 3.5
Project site
Shan (%) 32.6 35.5
Yangon 27.6 30.9 0.105
Gweru 39.8 33.6
ART before TB treatment start
Yes (%) 16.5 27.2 ,0.001
ART before TB treatment end
Yes (%) 82.3 76.9 0.027
BMI category at TB treatment start (kg/m
2)
,16 (%) 24.1 22.9
16–18.49 37.4 36.1 0.069
18.5–24.99 36.9 36.7
$25 1.6 4.3
Subsamples with non-missing values
CD4 count at TB treatment start (/mm
3)
n 316 241
#100 (%) 61.7 52.7
101–200 20.6 22.8 0.099
201–350 11.4 17.8
.350 6.3 6.7
ART=antiretroviral therapy. TB=tuberculosis.
A total of 81 deaths and 126 unfavorable outcomes were recorded among the 605 smear negative TB patients, compared to 69 deaths and 120 unfavorable outcomes
among the sample of 485 extrapulmonary individuals. The log rank test for equality of survivor functions shows that the data are consistent with no difference in
survivor functions for mortality or unfavorable treatment outcomes between the smear-negative and extrapulmonary TB patient samples (p=0.908 and 0.451,
respectively).
doi:10.1371/journal.pone.0035948.t002
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diagnostic and treatment guidelines, not only for TB and ART,
but also for malnutrition and HIV opportunistic illnesses, changed
during this time. In order to control for ART status, an important
confounder, it was adjusted for as a time-dependent covariate.
This study was conducted with data collected before greater access
to rapid molecular diagnostics became available in the programme
areas, thus patients were diagnosed according to clinical
algorithms which included clinical assessment, sputum microscopy
and chest radiography based on WHO guidelines [28]. The lack of
mycobacterial culture for diagnosis means that it is likely that not
all patients actually had TB. In the absence of culture and drug
sensitivity testing this study focused on new TB patients. It is also
possible that there were some cases of drug-resistant TB. However,
such numbers are likely to be small given that the prevalence of
multi-drug-resistant TB among new patients in 2008 was
estimated at 1.9% in Zimbabwe and 4.2% in Myanmar [15,16].
Further, data on occurrence of immune reconstitution inflam-
matory syndrome (IRIS) was not systematically available in this
routine programmatic database, and was therefore not included in
the analysis. TB IRIS is very common and could potentially have
contributed to reduction or lack of change in BMI. However, as
our primary outcome measure is mortality during TB treatment,
and BMI category is a simple interim measure that can be
included in routine programme monitoring, the lack of data on TB
IRIS does not change the interpretation of our findings. Previous
studies have shown that a proportion of TB treatment defaulters
(8.4% of our initial sample) may in fact have died [29], and thus
we may have underestimated the number of TB treatment deaths.
Finally, individuals with height and weight measurements
available were somewhat different from patients without these
measurements, particularly in regards to distribution by project
and ART status, although their survivor functions do not differ
(Appendix S3).
In summary, our findings reveal that remaining severely
underweight or losing a BMI category during the first month of
TB treatment can predict treatment outcome among new adult
HIV-positive individuals with smear-negative and extrapulmonary
TB. Currently, there are no interim programme monitoring
indicators for this group of patients, reported to have the highest
risk of mortality and unfavourable outcomes in countries with high
prevalence of HIV and TB [7,13,14,30–33]. There is an urgent
need for interim monitoring of both individual patients and patient
cohorts in areas with a high prevalence of HIV and TB. BMI
change monitoring is a simple and inexpensive tool that is feasible
to implement under routine programmatic conditions in resource-
limited settings. Patients identified as being at high risk could
benefit from more intensive monitoring, nutritional supplementa-
tion and be prioritized for further investigations, such as culture
and multi-drug-resistant TB testing, which may not be feasible for
all TB patients in such settings. Further research is needed to
evaluate whether the use of this interim marker can help improve
patient outcomes through such earlier and more efficient use of
patient monitoring, investigations and support.
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Table 3. Univariable and multivariable association of BMI category change with TB treatment mortality.
Main sample (n=1090) Crude Adjusted #
n
Number
of deaths HR 95% CI p-value* HR 95% CI p-value*
Remained severely underweight or lost a BMI category 299 80 3.44 2.50–4.75 ,0.001 4.05 2.77–5.91 ,0.001
Stable or increased BMI category 791 70 1 1
Sub-sample (n=557) Crude Adjusted ##
Patients with CD4 count at TB treatment start n
Number
of deaths HR 95% CI p-value* HR 95% CI p-value*
Remained severely underweight or lost a BMI category 168 50 4.24 2.71–6.64 ,0.001 5.25 3.09–8.91 ,0.001
Stable or increased BMI category 389 31 1 1
*p-value of likelihood ratio test.
#Adjusted for sex, age group, project, ART as time dependent variable and BMI category at TB treatment start.
##Adjusted for sex, age group, project, ART as time dependent variable, BMI category and CD4 category at TB treatment start.
CI=confidence interval. HR=hazard ratio. TB=tuberculosis. ART=antiretroviral therapy. BMI=body mass index.
doi:10.1371/journal.pone.0035948.t003
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